Head of Operations
Head of Operations, Oxford Respiratory Trials Unit
I have worked at the Oxford Respiratory Trials Unit since 2009. My current role involves managing a team of research professionals to deliver the trials being run through the unit. I ensure that appropriate funding, systems and resources are in place to ensure trials are delivered on time and within budget, and meet the appropriate clinical trial and research governance requirements.
Prior to joining ORTU I worked in the Pharmaceutical/Biotech Industry for over 10 years. I have worked across a range of therapeutic areas and phases of trials in various roles including trial management and monitoring, data management, feasibility and strategy development.
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Gbinigie O. et al, (2023), BMJ open, 13
The randomised thoracoscopic talc poudrage+indwelling pleural catheters versus thoracoscopic talc poudrage only in malignant pleural effusion trial (TACTIC): study protocol for a randomised controlled trial.
Dipper A. et al, (2023), BMJ open respiratory research, 10
Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial
Llewelyn MJ. et al, (2023), The Lancet Infectious Diseases, 23, 207 - 221
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Butler CC. et al, (2023), The Lancet, 401, 281 - 293
Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial
Butler C. et al, (2022)